KalVista Pharmaceuticals (FRA:4XC1) ROCE % : -120.74% (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. KalVista Pharmaceuticals's annualized ROCE % for the quarter that ended in Jan. 2024 was -120.74%.

KalVista Pharmaceuticals ROCE % Historical Data

The historical data trend for KalVista Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals ROCE % Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

ROCE %

Get a 7-Day Free Trial

-44.17

-44.63

-32.58

-45.04

-61.01

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-60.28	-69.85	-73.69	-91.33	-120.74

KalVista Pharmaceuticals ROCE % Calculation

KalVista Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Apr. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	-101.114	/	( ( (188.793 - 10.719)	+	(167.08 - 13.709) )	/ 2 )
	=	-101.114	/	( (178.074	+	153.371)	/ 2 )
	=	-101.114	/	165.7225
	=	-61.01 %

KalVista Pharmaceuticals's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-121.732	/	( ( (131.39 - 16.81)	+	(104.623 - 17.56) )	/ 2 )
	=	-121.732	/	( ( 114.58	+	87.063 )	/ 2 )
	=	-121.732	/	100.8215
	=	-120.74 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

KalVista Pharmaceuticals (FRA:4XC1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

KalVista Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (FRA:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KALV:USA

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (FRA:4XC1) Headlines

No Headlines